[HTML][HTML] Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin
F Sun, Y Liu, T Gong, Q Pan, T Xiang, J Zhao… - Cell Death & …, 2021 - nature.com
Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin.
F Sun, Y Liu, T Gong, Q Pan, T Xiang… - Cell Death & …, 2021 - search.ebscohost.com
Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin.
F Sun, Y Liu, T Gong, Q Pan, T Xiang, J Zhao… - Cell Death & …, 2021 - europepmc.org
Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin
F Sun, Y Liu, T Gong, Q Pan, T Xiang… - Cell death & …, 2021 - pubmed.ncbi.nlm.nih.gov
Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin
S Fengze, Y Liu, G Tingting, P Qiuzhong… - Cell Death and …, 2021 - search.proquest.com
Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
[HTML][HTML] Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin
F Sun, Y Liu, T Gong, Q Pan, T Xiang, J Zhao… - Cell Death & …, 2021 - ncbi.nlm.nih.gov
Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …
the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to …